VELCADE 3.5MG FOR INJECTION [SIN13064P]

Product Info

VELCADE 3.5MG FOR INJECTION

[SIN13064P]

Indication

Indications
VELCADE® (bortezomib) for Injection is indicated as part of combination therapy for the treatment of patients with previously untreated multiple myeloma.
VELCADE® (bortezomib) for Injection is indicated as monotherapy for the treatment of patients with multiple myeloma who have received at least 1 prior therapy.
VELCADE® (bortezomib) for Injection is indicated as monotherapy for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

VELCADE® (bortezomib) for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Dosing

Dosage and Administration
VELCADE® may be administered:

• Intravenously (at a concentration of 1 mg/ml) as a 3 to 5 second bolus injection or

• Subcutaneously (at a concentration of 2.5 mg/ml)

Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered.

At least 72 hours should elapse between consecutive doses of VELCADE®.

VELCADE® IS FOR INTRAVENOUS OR SUBCUTANEOUS USE ONLY. Intrathecal administration has resulted in death.

Monotherapy
Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma
Recommended Dosage
The recommended dose of VELCADE® is 1.3 mg/m²/dose administered twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12–21). For extended therapy of more than 8 cycles, VELCADE® may be administered on the standard schedule or, for relapsed multiple myeloma, on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35) (see Clinical Trials section for a description of dose administration during the trials – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). At least 72 hours should elapse between consecutive doses of VELCADE®.

Dose Modification and Re-initiation of Therapy
VELCADE® therapy should be withheld at the onset of any Grade 3 non-hematological or Grade 4 hematological toxicities excluding neuropathy as discussed below (see Warnings And Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Once the symptoms of the toxicity have resolved, VELCADE® therapy may be reinitiated at a 25% reduced dose (1.3 mg/m²/dose reduced to 1.0 mg/m²/dose; 1.0 mg/m²/dose reduced to 0.7 mg/m²/dose).

Neuropathic Pain and/or Peripheral Sensory Neuropathy
Table 1 contains the recommended dose modification for the management of patients who experience VELCADE®-related neuropathic pain and/or peripheral neuropathy. Severe autonomic neuropathy resulting in treatment interruption or discontinuation has been reported. Patients with pre-existing severe neuropathy should be treated with VELCADE® only after careful risk-benefit assessment.

Combination Therapy
Previously Untreated Multiple Myeloma
Recommended Dosage in Combination with Melphalan and Prednisone
VELCADE® (bortezomib) for Injection is administered in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles as shown in Table 2. In Cycles 1–4, VELCADE® is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5–9, VELCADE® is administered once weekly (days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of VELCADE®.

Dose Management Guidelines for Combination Therapy with Melphalan and Prednisone
Dose modification and reinitiation of therapy when VELCADE® is administered in combination with melphalan and prednisone

Prior to initiating a new cycle of therapy:

• Platelet count should be ≥70 x 10⁹/L and the absolute neutrophil count (ANC) should be ≥ 1.0 x 10⁹/L

• Non-hematological toxicities should have resolved to Grade 1 or baseline

For additional information concerning melphalan and prednisone, see manufacturer's prescribing information.

Previously Untreated Mantle Cell Lymphoma Patients Not Eligible for Haematopoietic Stem Cell Transplantation
Recommended Dosage in Combination with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone
For VELCADE® dosage, see Monotherapy. Six VELCADE® cycles are administered. For patients with a response first documented at Cycle 6, two additional VELCADE® cycles are recommended.

The following medicinal products are administered on Day 1 of each VELCADE® 3 week treatment cycle as intravenous infusions: rituximab at 375 mg/m², cyclophosphamide at 750 mg/m², and doxorubicin at 50 mg/m². Prednisone is administered orally at 100 mg/m² on Days 1, 2, 3, 4 and 5 of each treatment cycle.

Dose Adjustments during Treatment for Patients with Previously Untreated Mantle Cell Lymphoma
Prior to the first day of each cycle (other than Cycle 1):

• Platelet count should be ≥ 100 x 10⁹/L and absolute neutrophil count (ANC) should be ≥ 1.5 x 10⁹/L

• Hemoglobin should be ≥ 8 g/dL (≥ 4.96 mmol/L)

• Non-hematologic toxicity should have recovered to Grade 1 or baseline

VELCADE® treatment must be withheld at the onset of any Grade 3 non-hematological or Grade 3 hematological toxicities, excluding neuropathy (see Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). For dose adjustments, see Table 4 below.

For dosing instructions for rituximab, cyclophosphamide, doxorubicin, or prednisone, see manufacturer's prescribing information.

Special Patient Populations
Impaired Renal Function
The pharmacokinetics of VELCADE® are not influenced by the degree of renal impairment. Therefore, dosing adjustments of VELCADE® are not necessary for patients with renal insufficiency. Since dialysis may reduce VELCADE® concentrations, the drug should be administered after the dialysis procedure (see Pharmacokinetic Properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Impaired Hepatic Function
Patients with mild hepatic impairment do not require a starting dose adjustment and should be treated per the recommended VELCADE® dose. Patients with moderate or severe hepatic impairment should be started on VELCADE® at a reduced dose of 0.7 mg/m² per injection during the first cycle, and a subsequent dose escalation to 1.0mg/m² or further dose reduction to 0.5mg/m² may be considered based on patient tolerance (see Table 5 and Pharmacokinetic Properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Method of Administration
VELCADE® is administered intravenously or subcutaneously. When administered intravenously, VELCADE® is administered as a 3–5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with 0.9% sodium chloride solution for injection. For subcutaneous administration, the reconstituted solution is injected into the thighs (right or left) or abdomen (right or left). Injection sites should be rotated for successive injections.
If local injection site reactions occur following VELCADE® injection subcutaneously, a less concentrated VELCADE® solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously, or changed to IV injection.

Contraindications

Contraindications
VELCADE® is contraindicated in patients with acute diffuse infiltrative pulmonary and pericardial disease and hypersensitivity to bortezomib, boron, or mannitol.